Genelux Co. (NASDAQ:GNLX – Get Rating) shares hit a new 52-week high during trading on Monday . The stock traded as high as $21.96 and last traded at $21.92, with a volume of 132537 shares traded. The stock had previously closed at $18.47.
Wall Street Analysts Forecast Growth
Separately, Benchmark assumed coverage on shares of Genelux in a research report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 target price on the stock.
Genelux Stock Down 4.7 %
About Genelux
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
- Latest Tech Layoffs at Dell May Provide Buying Opportunity
- Here's What Happens When a Stock is Removed from an Index
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.